Can 4 therapy sessions ease death anxiety in advanced cancer?
NCT ID NCT07105033
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests a program called Focused Acceptance and Commitment Therapy (FACT) for advanced cancer patients who feel anxious about death. 70 participants will attend four weekly 35-45 minute sessions to learn coping skills. The goal is to see if FACT is safe, acceptable, and helps reduce death-related anxiety.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Focused Acceptance and Commitment Therapy (FACT) sessions
- What this could lead to
- If it works, this could provide a short, practical therapy to help advanced cancer patients cope with fear of death.
- What could go wrong
- This is a small, early pilot study (70 people) with no control group for efficacy. The therapy may not reduce anxiety more than usual care, and results may not apply to all cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A lifeline for cancer caregivers: can simple phone support reduce their stress?
- A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
- Can a 30-hour e-learning course equip family doctors to deliver better palliative care?
- Can a new nucleotide analogue boost cancer treatment?
- Can a cancer vaccine train the body to fight advanced tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?